Nicotine acutely inhibits erectile tumescence by altering heart rate variability.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

To examine potential mechanisms underlying nicotine's effects on male sexual arousal by exploring the mediating role of heart rate variability (HRV).

During each laboratory visit, time-domain parameters of HRV (standard deviation of normal-to-normal [NN] intervals, square root of the mean squared difference of successive NN intervals, and percent of NN intervals for which successive heartbeat intervals differed by at least 50 ms [pNN50]) along with the objective (via penile plethysmography) and subjective indices of sexual arousal were assessed.

Who Took Part

PubMed indexes the participants as teenagers, young adults and adults, men only.

The sample comprised 22 healthy, nicotine-naïve men (mean age = 20.91 years; standard deviation = 2.43).

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.

In the crossover set-up each of the participants took both Therapeutic nicotine (patch, non-peptide) and the comparison in turn, acting as their own control.

Data were taken from a double-blind, randomized, placebo-controlled, crossover trial previously completed and published elsewhere.

What Was Measured

PubMed files the paper under topics including Heart Rate, Nicotine and Penile Erection.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (Urology), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.